Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood (2023) 142 (Supplement 1): 624.

https://doi.org/10.1182/blood-2023-179291

Published: 2023

Journal Articles

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2023-180561

Published: 2023

Journal Articles

Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study

Masataka Kuwana, Tomoki Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Kensuke Naito, Shingo Kurahashi, Toshiya Kagoo, Kazuki Tanimoto, Natsuko Shichiri, So Saotome, Esteban Masuda, Yoshiaki Tomiyama

Blood (2023) 142 (Supplement 1): 2578.

https://doi.org/10.1182/blood-2023-182113

Published: 2023

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study

Masaaki Hotta, Ayako Iwama, Tokiko Hoshiyama, Yukie Tsubokura, Hideaki Yoshimura, Yumiko Kono, Shinya Fujita, Atsushi Satake, Tomoki Ito

Blood (2023) 142 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2023-173434

Published: 2023

Journal Articles

Interim Phase I Safety Study of Anti-Transferrin Receptor Antibody(PPMX-T003) in Patients with Polycythemia Vera

Tomoki Ito, Teruhito Takakuwa, Masayuki Hino, Hirohisa Nakamae, Tadashi Matsuura

Blood (2023) 142 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2023-174193

Published: 2023

Journal Articles

Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study

Blood (2022) 140 (Supplement 1): 11244–11245.

https://doi.org/10.1182/blood-2022-169782

Published: 2022

Journal Articles

Yittrium 90 Ibritumomab Tiuxetan (Zevalin®) in the Treatment of Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma; Integrated Analysis of Three Japanese Institution's Experience with Improvement Trend of the Long-Term Responses over a 10 Year Study Period

Ilseung Choi, MD, Masaya Okada, MD, Tomoki Ito, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-138386

Published: 2020

Journal Articles

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Masaaki Hotta, MD, Atsushi Satake, MD PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 4342.

https://doi.org/10.1182/blood-2019-129680

Published: 2019

Journal Articles

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Masaaki Hotta, MD, Satake Atsushi, MD PhD, Yukie Tsubokura, MD, Yoshiko Azuma, MD, Hideaki Yoshimura, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Tomoki Ito, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 5672.

https://doi.org/10.1182/blood-2019-129959

Published: 2019

Journal Articles

Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?

Aya Nakaya, MD PhD, Shinya Fujita, MD PhD, Atsushi Satake, MD PhD, Takahisa Nakanishi, MD PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Ryo Saito, MD, Akiko Konishi, MD, Masaaki Hotta, MD, Hideaki Yoshimura, MD, Kazuyoshi Ishii, MD MPH, PhD, Tomoki Ito, MD PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 5402.

https://doi.org/10.1182/blood-2018-99-117823

Published: 2018

Journal Articles

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2018-99-113282

Published: 2018

Journal Articles

A Critical Role of Host-Derived Semaphorin-4A for Regulating T Cell Immune Responses in Acute Graft Versus Host Disease

Hideaki Yoshimura, MD, Yukie Tsubokura, MD, Masaaki Hotta, MD, Atsushi Satake, MD PhD, Tomoki Ito, MD PhD, Atsushi Kumanogoh, MD PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2018-99-113853

Published: 2018

Journal Articles

Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis

Atsushi Satake, MD PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Tomoki Ito, MD PhD, Kazuyoshi Ishii, Shosaku Nomura, MD PhD

Blood (2017) 130 (Supplement 1): 4092.

https://doi.org/10.1182/blood.V130.Suppl_1.4092.4092

Published: 2017

Journal Articles

Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells

Tomoki Ito, MD PhD, Kayoko Kibata, MD, Muneo Inaba, PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2017) 130 (Supplement 1): 1007.

https://doi.org/10.1182/blood.V130.Suppl_1.1007.1007

Published: 2017

Journal Articles

Immunomodulatory Drugs (IMiDs), Lenalidomide and Pomalidomide, Suppress Th1-Inducing Capacity of Dendritic Cells but Enhance Th2-Mediated Allergic Response

Tomoki Ito, M. D. and Ph. D., Phan Thi Xuan Vien, Muneo Inaba, Ph. D, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MD MPH, PhD, Shosaku Nomura, MD PhD

Blood (2016) 128 (22): 2520.

https://doi.org/10.1182/blood.V128.22.2520.2520

Published: 2016

Journal Articles

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Study in Japan

Blood (2015) 126 (23): 4341.

https://doi.org/10.1182/blood.V126.23.4341.4341

Published: 2015

Journal Articles

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation

Kazuyoshi Ishii, MD MPH, PhD, Shosaku Nomura, MD PhD, Tomoki Ito, MD PhD, Yuta Katayama, MD PhD, Taiichi Kyo, MD, Shuichi Ota, MD PhD, Masanori Seki, MD PhD, Shigeru Chiba, MD PhD, Yoshinobu Maeda, MD PhD, Mitsune Tanimoto, MD PhD, Takayuki Ikezoe, MD PhD, Hideo Yagi, MD PhD, Yoji Ishida, MD, PhD, Naohito Fujishima, MD PhD, Kenichi Sawada, MDPhD

Blood (2014) 124 (21): 5089.

https://doi.org/10.1182/blood.V124.21.5089.5089

Published: 2014

Journal Articles

Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation

Kazuyoshi Ishii, MD, MPH, PhD, Shosaku Nomura, MD, PhD, Tomoki Ito, MD, PhD, Yuta Katayama, MD, PhD, Taiichi Kyo, MD, Shuichi Ota, MD, PhD, Masanori Seki, MD, PhD, Shigeru Chiba, MD, PhD, Yoshinobu Maeda, M.D., Ph.D., Mitsune Tanimoto, MD, PhD, Takayuki Ikezoe, MD. PhD, Hideo Yagi, MD, PhD, Yoji Ishida, M.D., Ph.D., Naohito Fujishima, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2013) 122 (21): 5454.

https://doi.org/10.1182/blood.V122.21.5454.5454

Published: 2013

Journal Articles

Evaluation Of Large Granular Lymphocytes and Endothelial-Cell-Related Biomarkers In Patients With Chronic Myeloblastic Leukemia: Comparison Among 3 TKIs

Tomoki Ito, MD, PhD, Nobuhiko Uoshima, MD, PhD, Yasuhiro Maeda, Masaaki Hotta, Hideaki Yoshomura, Shinya Fujita, Atsushi Satake, MD, PhD, Kazuyoshi Ishii, MD, MPH, PhD, Fumiaki Urase, Kunio Hayashi, PhD/MD, Shosaku Nomura, MD, PhD

Blood (2013) 122 (21): 5167.

https://doi.org/10.1182/blood.V122.21.5167.5167

Published: 2013

Journal Articles

Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70

Joanne Shaw, Yui-Hsi Wang, Tomoki Ito, Kazuhiko Arima, Yong-Jun Liu

Blood (2010) 115 (15): 3051–3057.

https://doi.org/10.1182/blood-2009-08-239145

Published: 2010

NARROW

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study

Interim Phase I Safety Study of Anti-Transferrin Receptor Antibody(PPMX-T003) in Patients with Polycythemia Vera

Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study

Yittrium 90 Ibritumomab Tiuxetan (Zevalin®) in the Treatment of Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma; Integrated Analysis of Three Japanese Institution's Experience with Improvement Trend of the Long-Term Responses over a 10 Year Study Period

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

A Critical Role of Host-Derived Semaphorin-4A for Regulating T Cell Immune Responses in Acute Graft Versus Host Disease

Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis

Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells

Immunomodulatory Drugs (IMiDs), Lenalidomide and Pomalidomide, Suppress Th1-Inducing Capacity of Dendritic Cells but Enhance Th2-Mediated Allergic Response

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Study in Japan

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation

Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation

Evaluation Of Large Granular Lymphocytes and Endothelial-Cell-Related Biomarkers In Patients With Chronic Myeloblastic Leukemia: Comparison Among 3 TKIs

Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only